Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Merck Serono

Drug Profile

Interferon beta-1a - Merck Serono

Alternative Names: Interferon β-1a - Merck Serono; r-IFNβ-1a; Rebif; Rebif Rebidose; Rebif® modified formulation; Rebif® New Formulation; Rebif® reformulation; Rebif® Serum-free formulation; Recombinant human interferon beta-1a; RNF - Merck Serono; scIFNβ-1a

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer EMD Serono; Merck Serono
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Hepatitis C; Human papillomavirus infections; Non-small cell lung cancer; Ulcerative colitis
  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 11 Sep 2019 Additional efficacy data from the phase III REFLEX trial in Multiple sclerosis presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2019)
  • 31 Dec 2014 Biomarkers information updated
  • 06 May 2014 EMD Serono plans a phase IV RESOunD trial for Multiple Sclerosis in USA (NCT02117050)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top